Uveitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 194 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2016, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 2, 1, 26 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Uveitis.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uveitis Overview 8
Therapeutics Development 9
Pipeline Products for Uveitis - Overview 9
Pipeline Products for Uveitis - Comparative Analysis 10
Uveitis - Therapeutics under Development by Companies 11
Uveitis - Therapeutics under Investigation by Universities/Institutes 15
Uveitis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Uveitis - Products under Development by Companies 19
Uveitis - Products under Investigation by Universities/Institutes 22
Uveitis - Companies Involved in Therapeutics Development 23
2-BBB Medicines BV 23
AbbVie Inc 24
Aciont Inc. 25
Aldeyra Therapeutics Inc 26
Apitope International NV 27
Astellas Pharma Inc. 28
Bionomics Limited 29
Bristol-Myers Squibb Company 30
Can-Fite BioPharma Ltd. 31
Clearside BioMedical, Inc. 32
Endocyte, Inc. 33
Enzo Biochem, Inc. 34
EyeGate Pharmaceuticals, Inc. 35
F. Hoffmann-La Roche Ltd. 36
HanAll Biopharma Co., Ltd. 37
Icon Bioscience, Inc. 38
KPI Therapeutics, Inc. 39
Midatech Pharma Plc 40
Mitotech S.A. 41
Neuroptis Biotech 42
Novartis AG 43
Oculis ehf 44
OncoNOx ApS 45
OSE Immunotherapeutics 46
Palatin Technologies, Inc. 47
Panoptes Pharma Ges.m.b.H. 48
Pfizer Inc. 49
Precision Ocular Ltd 50
pSivida Corp. 51
Regeneron Pharmaceuticals Inc 52
Santen Pharmaceutical Co., Ltd. 53
SynDevRx, Inc. 54
TopiVert Ltd 55
TxCell SA 56
Uveitis - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Target 58
Assessment by Mechanism of Action 61
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
2-B3201 - Drug Profile 68
abatacept - Drug Profile 70
adalimumab - Drug Profile 75
ANV-103 - Drug Profile 83
ATXUV-1 - Drug Profile 84
ATXUV-2 - Drug Profile 85
B27-PD - Drug Profile 86
BNC-164 - Drug Profile 87
celecoxib - Drug Profile 88
Col-Treg - Drug Profile 90
CVX-001 - Drug Profile 92
cyclosporine SR - Drug Profile 93
dalazatide - Drug Profile 94
dexamethasone acetate - Drug Profile 99
dexamethasone acetate - Drug Profile 103
dexamethasone acetate - Drug Profile 104
dexamethasone sodium phosphate - Drug Profile 105
Drug for Chronic Uveitis - Drug Profile 107
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 108
EBI-031 - Drug Profile 109
EC-1669 - Drug Profile 110
EYS-606 - Drug Profile 111
fluocinolone acetonide SR - Drug Profile 112
FR-104 - Drug Profile 120
Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 123
HL-036 - Drug Profile 124
HO-10 - Drug Profile 125
INV-17 - Drug Profile 126
IVMED-10 - Drug Profile 127
IVMED-20 - Drug Profile 128
KPI-190 - Drug Profile 129
LME-636 - Drug Profile 130
lodamin - Drug Profile 131
methotrexate - Drug Profile 132
NOP-3 - Drug Profile 133
NS-2 - Drug Profile 134
OX-1001 - Drug Profile 138
piclidenoson - Drug Profile 139
PL-8177 - Drug Profile 147
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 148
PP-001 - Drug Profile 150
PPL-003 - Drug Profile 151
Recombinant Enzymes for Uveitis - Drug Profile 153
sarilumab - Drug Profile 154
sirolimus - Drug Profile 159
Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 161
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 162
tesidolumab - Drug Profile 164
TOP-1288 - Drug Profile 166
triamcinolone acetonide - Drug Profile 167
Uveitis - Dormant Projects 171
Uveitis - Discontinued Products 175
Uveitis - Product Development Milestones 176
Featured News & Press Releases 176
Appendix 189
Methodology 189
Coverage 189
Secondary Research 189
Primary Research 189
Expert Panel Validation 189
Contact Us 189
Disclaimer 190

List of Tables

Number of Products under Development for Uveitis, H2 2016 13
Number of Products under Development for Uveitis - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2016 26
Uveitis - Pipeline by 2-BBB Medicines BV, H2 2016 27
Uveitis - Pipeline by AbbVie Inc, H2 2016 28
Uveitis - Pipeline by Aciont Inc., H2 2016 29
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016 30
Uveitis - Pipeline by Apitope International NV, H2 2016 31
Uveitis - Pipeline by Astellas Pharma Inc., H2 2016 32
Uveitis - Pipeline by Bionomics Limited, H2 2016 33
Uveitis - Pipeline by Bristol-Myers Squibb Company, H2 2016 34
Uveitis - Pipeline by Can-Fite BioPharma Ltd., H2 2016 35
Uveitis - Pipeline by Clearside BioMedical, Inc., H2 2016 36
Uveitis - Pipeline by Endocyte, Inc., H2 2016 37
Uveitis - Pipeline by Enzo Biochem, Inc., H2 2016 38
Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 39
Uveitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 40
Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 41
Uveitis - Pipeline by Icon Bioscience, Inc., H2 2016 42
Uveitis - Pipeline by KPI Therapeutics, Inc., H2 2016 43
Uveitis - Pipeline by Midatech Pharma Plc, H2 2016 44
Uveitis - Pipeline by Mitotech S.A., H2 2016 45
Uveitis - Pipeline by Neuroptis Biotech, H2 2016 46
Uveitis - Pipeline by Novartis AG, H2 2016 47
Uveitis - Pipeline by Oculis ehf, H2 2016 48
Uveitis - Pipeline by OncoNOx ApS, H2 2016 49
Uveitis - Pipeline by OSE Immunotherapeutics, H2 2016 50
Uveitis - Pipeline by Palatin Technologies, Inc., H2 2016 51
Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016 52
Uveitis - Pipeline by Pfizer Inc., H2 2016 53
Uveitis - Pipeline by Precision Ocular Ltd, H2 2016 54
Uveitis - Pipeline by pSivida Corp., H2 2016 55
Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 56
Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 57
Uveitis - Pipeline by SynDevRx, Inc., H2 2016 58
Uveitis - Pipeline by TopiVert Ltd, H2 2016 59
Uveitis - Pipeline by TxCell SA, H2 2016 60
Assessment by Monotherapy Products, H2 2016 61
Number of Products by Stage and Target, H2 2016 63
Number of Products by Stage and Mechanism of Action, H2 2016 66
Number of Products by Stage and Route of Administration, H2 2016 69
Number of Products by Stage and Molecule Type, H2 2016 71
Uveitis - Dormant Projects, H2 2016 175
Uveitis - Dormant Projects (Contd..1), H2 2016 176
Uveitis - Dormant Projects (Contd..2), H2 2016 177
Uveitis - Dormant Projects (Contd..3), H2 2016 178
Uveitis - Discontinued Products, H2 2016 179